UBS analyst Matthew Weston maintained a Buy rating on Sanofi today and set a price target of €105.00. The company’s shares closed last Wednesday at $99.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Weston covers the Healthcare sector, focusing on stocks such as Novo Nordisk, Novartis AG, and Sanofi. According to TipRanks, Weston has an average return of 6.8% and a 71.08% success rate on recommended stocks.
In addition to UBS, Sanofi also received a Buy from TR | OpenAI – 4o’s Veda Pharmyne in a report issued yesterday. However, on September 26, Goldman Sachs maintained a Hold rating on Sanofi (Other OTC: SNYNF).
Based on Sanofi’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $10.74 billion and a net profit of $3.94 billion. In comparison, last year the company earned a revenue of $11.38 billion and had a net profit of $1.11 billion
Read More on SNYNF:
Disclaimer & DisclosureReport an Issue
- Sanofi’s Promising Phase 3 Study on Duvakitug for Crohn’s Disease
- Sanofi’s Phase 3 Study on Duvakitug: A Potential Game-Changer for Ulcerative Colitis
- Sanofi’s Promising Phase 3 Study on Duvakitug for Ulcerative Colitis
- Sanofi’s Phase 3 Study on Duvakitug: A Potential Game-Changer for Crohn’s Disease Treatment
- Revvity announces program to expand type 1 diabetes offering
/A%20Lucid%20Motors%20vehicle%20parked%20in%20front%20of%20a%20showroom_%20Image%20by%20Michael%20Berlfein%20via%20Shutterstock_.jpg)
/Broadcom%20Inc%20logo%20on%20phone%20and%20site-by%20Majahid%20Mottakin%20via%20Shutterstock.jpg)
/Tesla%20Inc%20logo%20by-%20baileystock%20via%20iStock.jpg)
